Efficacy and safety of low- to medium-dose telitacicept in adults with high-risk progressive IgA nephropathy: a retrospective real-world study.

A sensitivity analysis confirmed that after excluding these two patients, the efficacy in the remaining nine patients remained highly significant (61.24% proteinuria reduction, p < 0.001; 26.61% eGFR increase, p = 0.008).

also in 132,142 other papers